OP23: FETAL STRUCTURAL ANOMALIES
Objectives: To investigate women's preferred timing of screening for fetal structural anomalies, to explore women's knowledge and understanding of prenatal screening and to evaluate screening-related anxiety. Methods: As part of a prospective study offering an early anomaly scan at about 13 weeks' gestation, carried out in the north of the Netherlands, 1037 women were asked to complete two online questionnaires on their decision and motives to opt for or decline the 13-week scan. The questionnaires were filled in before and after the scan. The state-trait anxiety inventory scale (STAI) was used to measure changes in anxiety while the positive and negative affect schedule (PANAS) was used to assess patient's affect in the two moments. The SUM-score method was used to evaluate knowledge. Stress levels and affect changes were compared by means of paired-sample T-test.
Results: Ninety-three-percent (n=977) of women had a partner and 50% (n=522) already had children; 28.7% (n=300) had experience a previous miscarriage and 4.7% (n=48) had undergone a termination of pregnancy. The great majority of the women (98.69%, n=904) chose for the 13-week scan. Ninety-eight percent (n=1026) expressed their wish to be informed as early as possible in pregnancy about possible fetal structural anomalies. Although no significant affect difference was shown in the participants before and after the 13-week scan (p=0.691), women reported significantly lower (p<0.01) anxiety levels after the 13-week scan compared to before the ultrasound examination. Knowledge of the goals of the screening program was good in 75.2%, sufficient in 21.8% and insufficient in 3% of the women. Also, 91% of women seemed to understand the strengths and limitations of the 13 -week scan.
Conclusions:
The great majority of women (98.2%) wishes to know as early as possible in pregnancy if fetal structural anomalies are present. Finally, undergoing the 13-week anomaly scan significantly reduced anxiety levels in mothers who opted for it. We communicate prenatal diagnosis of fetal neuroblastoma in four cases.
Patient was referred at 32 weeks of gestation with diagnosis of kidney cyst. Ultrasound examination and MRI showed a 33 mm. diameter heterogeneous lesion located on the right supra renal gland, no vessels were observed. Neuroblastoma diagnosis was proposed. The newborn was delivered by Caesarean section at 37 weeks, and neuroblastoma diagnosis confirmed. Conservative management was decided.
Female patient referred with 30 weeks pregnancy. Ultrasonography examination and fetal MRI revealed a 25 mm hyper echogenic mass above the right kidney, no vascularisation was found in the lesion. Due to these findings, neuroblastoma diagnosis was made. Caesarean section was performed at 38 week gestation, and neuroblastoma diagnosis confirmed. Conservative management was decided but, two years later, MRI showed malignant signs. Surgery was performed with a total excision, with subsequent favourable evolution.
Patient was referred at 28 weeks. Ultrasound examination shows hyper echogenic image in left adrenal of 14 mm diameter. Neuroblastoma diagnosis was made. Newborn was delivered at 38 weeks. Newborn ultrasound examination, until six months, shows progressively regression of mass. Diagnosis of neuroblastoma versus adrenal hemorrhage was suggested.
Patient referred with a 34 week pregnancy. Ultrasound examination showed a 70 mm, not vascularised hyper echogenic image located on the left kidney upper pole. The lesion compressed the aorta and inferior vena cava, also fetal hydrops and polyhydramnios was seen. Neuroblastoma diagnosis was suggested. Caesarean section was performed at 34 weeks. 6 days later due to multiple organ failure, the newborn dies. Autopsy confirmed neuroblatoma diagnosis plus heart, liver and lung metastasis.
